PHILADELPHIA, Oct. 1, 2018 /PRNewswire/ -- Virion Therapeutics, LLC, developers of the first checkpoint inhibitor poweredvaccines for treatment of cancers and chronic viral infections, today announced the appointment of its inaugural Board of Directors and Scientific Advisory Board. Members of each Board will serve a three-year term and help guide the company in advancing
The following people were named to the Board of Directors (along with the company's founders Andrew D. Luber, Pharm.D. and Bernard Rudnick, M.B.A.):
The following people were named to the Scientific Advisory Board:
"We are pleased to have such an esteemed and qualified Board of Directors and Scientific Advisory Board," said Bernard Rudnick, chief executive officer of Virion. "The innovative and novel approach of our first in class genetically encoded checkpoint inhibitor that can be delivered by vaccination resonated with our members and helped attract such a highly experienced group of people. We are excited to have them work with us on our current vaccine programs and help guide the company in the future."
"Virion's approach to treating chronic viral infections and cancers is innovative and offers potential treatment options for patients in whom current therapies are limited. I'm excited to help the company advance its programs into clinical trials," added Board of Directors member Teresa L. Wright, M.D.
Virion Therapeutics, LLC Virion Therapeutics, LLC, is a science driven company developing innovative immune-based treatments for virally associated cancers and chronic viral infections utilizing the first genetically encoded checkpoint inhibitor given via vaccination. Our vaccines represent novel and highly effective platforms to induce potent, diverse and sustained T cell-mediated immune responses, allowing us to target common diseases with unmet medical needs. Founded in early 2018 to advance technology licensed from The Wistar Institute, an international leader in biomedical research with special expertise in vaccine, cancer and infectious disease research, Virion has built an experienced biotechnology management team, augmented by its advisory board that has extensive domain knowledge in antiviral, vaccine and oncology therapeutic arenas.
View original content:http://www.prnewswire.com/news-releases/virion-therapeutics-llc-announces-its-inaugural-board-of-directors-and-scientific-advisory-board-members-300722019.html
SOURCE Virion Therapeutics, LLC
Subscribe to our Free Newsletters!